The product pipeline of 4SC includes several cancer drugs, which are in various stages of preclinical and clinical development. 4SC focuses on attractive fields such as cancer stem cells and other important molecular signaling pathways that contribute to the development and spread of cancer.

Our in-house research team focuses on identifying biomarkers to define specific patient populations and indications for successful clinical development of our core products resminostat, domatinostat (4SC-202) and 4SC-208.
Frank Hermann, M.D. | CDO

Cancer Stem Cells

What is a cancer stem cell?

Narrated by Dr. John Dick, Canadian Stem Cell Foundation

Cancer stem cells, like somatic stem cells, are multi-potent; they are able to self-renew and to generate more differentiated bulk tumor cells. They are also the ʻrootsʼ of the tumor, assuring its sustained growth. If disseminated, they cause metastasis and lead to new tumor lesions.

Cancer stem cells are often resistant to chemo- and radiotherapy and even after section, circulating cancer stem cells are often left behind. The result is a lifelong risk of tumor re-initiation and metastasis. So in order to achieve sustained remission, cancer stem cells must be completely eliminated.

4SC believes that 4SC-208 is a promising drug candidate in the field of cancer stem cells and intends to advance the compound into clinical studies in relevant cancer indications.

Share this page:

Follow us on: